Daewoong Pharmaceutical Co., Ltd (KRX:069620)
South Korea
· Delayed Price · Currency is KRW 143,300
-1,100 (-0.76%)
At close: Jun 27, 2025, 3:30 PM KST
Daewoong Pharmaceutical Revenue
Daewoong Pharmaceutical had revenue of 356.49B KRW in the quarter ending March 31, 2025, with 6.17% growth. This brings the company's revenue in the last twelve months to 1.44T, up 3.94% year-over-year. In the year 2024, Daewoong Pharmaceutical had annual revenue of 1.42T with 3.44% growth.
Revenue (ttm)
1,443.39B
Revenue Growth
+3.94%
P/S Ratio
1.14
Revenue / Employee
835.78M
Employees
1,727
Market Cap
1,648.85B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1,422.68B | 47.35B | 3.44% |
| Dec 31, 2023 | 1,375.33B | 95.24B | 7.44% |
| Dec 31, 2022 | 1,280.09B | 127.12B | 11.03% |
| Dec 31, 2021 | 1,152.98B | 97.55B | 9.24% |
| Dec 31, 2020 | 1,055.42B | -58.00B | -5.21% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,898.69B |
| Celltrion | 3,662.23B |
| ALTEOGEN | 151.65B |
| Yuhan | 2,114.76B |
| SK Biopharmaceuticals | 578.00B |
| HLB Co., Ltd. | 74.64B |
| PharmaResearch | 392.31B |
| Peptron | 4.30B |
Daewoong Pharmaceutical News
- 2 months ago - Sun Pharma launches FEXUCLUE 40 mg in India for treatment of Erosive Esophagitis - Business Upturn